Seres Therapeutics (Germany) Performance
| 1S9 Stock | EUR 0.84 0.01 1.20% |
On a scale of 0 to 100, Seres Therapeutics holds a performance score of 2. The entity has a beta of 0.79, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Seres Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Seres Therapeutics is expected to be smaller as well. Please check Seres Therapeutics' jensen alpha, sortino ratio, and the relationship between the information ratio and total risk alpha , to make a quick decision on whether Seres Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Seres Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Seres Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 116 M | |
| Total Cashflows From Investing Activities | 64.1 M |
Seres |
Seres Therapeutics Relative Risk vs. Return Landscape
If you would invest 89.00 in Seres Therapeutics on September 14, 2024 and sell it today you would lose (5.00) from holding Seres Therapeutics or give up 5.62% of portfolio value over 90 days. Seres Therapeutics is currently producing 0.2042% returns and takes up 7.943% volatility of returns over 90 trading days. Put another way, 70% of traded stocks are less volatile than Seres, and 96% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Seres Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Seres Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Seres Therapeutics, and traders can use it to determine the average amount a Seres Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0257
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 1S9 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.94 actual daily | 70 70% of assets are less volatile |
Expected Return
| 0.2 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Seres Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Seres Therapeutics by adding it to a well-diversified portfolio.
Seres Therapeutics Fundamentals Growth
Seres Stock prices reflect investors' perceptions of the future prospects and financial health of Seres Therapeutics, and Seres Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Seres Stock performance.
| Return On Equity | -1.9 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (17.02) % | |||
| Current Valuation | 582.79 M | |||
| Shares Outstanding | 124.59 M | |||
| Price To Book | 12.02 X | |||
| Price To Sales | 50.23 X | |||
| Revenue | 144.93 M | |||
| EBITDA | (56.72 M) | |||
| Cash And Equivalents | 253.62 M | |||
| Cash Per Share | 2.77 X | |||
| Total Debt | 24.64 M | |||
| Debt To Equity | 0.23 % | |||
| Book Value Per Share | 0.54 X | |||
| Cash Flow From Operations | 6.69 M | |||
| Earnings Per Share | (2.18) X | |||
| Total Asset | 354.86 M | |||
About Seres Therapeutics Performance
By analyzing Seres Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Seres Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Seres Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Seres Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. SERES THERAPEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 155 people.Things to note about Seres Therapeutics performance evaluation
Checking the ongoing alerts about Seres Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Seres Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Seres Therapeutics had very high historical volatility over the last 90 days | |
| Seres Therapeutics has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 144.93 M. Net Loss for the year was (65.58 M) with profit before overhead, payroll, taxes, and interest of 3.04 M. | |
| Over 86.0% of the company shares are owned by institutions such as pension funds |
- Analyzing Seres Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Seres Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Seres Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Seres Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Seres Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Seres Therapeutics' stock. These opinions can provide insight into Seres Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |